Published in Aliment Pharmacol Ther on February 01, 2004
Epidemiology of cancer of the small intestine. World J Gastrointest Oncol (2011) 1.75
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res (2012) 1.53
Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut (2005) 1.25
Colorectal cancer surveillance in inflammatory bowel disease: the search continues. World J Gastroenterol (2009) 1.24
Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica (2011) 1.13
Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr (2012) 1.10
Small bowel adenocarcinomas--existing evidence and evolving paradigms. Nat Rev Clin Oncol (2013) 0.99
Diagnostic accuracy of confocal laser endomicroscopy in diagnosing dysplasia in patients affected by long-standing ulcerative colitis. World J Gastrointest Endosc (2012) 0.95
Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines. Ann Gastroenterol (2012) 0.90
Small bowel adenocarcinoma in Crohn's disease: a case report and review of literature. World J Gastroenterol (2006) 0.90
Has the risk of colorectal cancer in inflammatory bowel disease decreased? World J Gastroenterol (2013) 0.88
Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease. Dig Dis Sci (2015) 0.85
A case of small bowel adenocarcinoma in a patient with Crohn's disease detected by PET/CT and double-balloon enteroscopy. World J Gastroenterol (2009) 0.85
Current trends in inflammatory bowel disease: the natural history. Therap Adv Gastroenterol (2010) 0.84
Small bowel adenocarcinoma and Crohn's disease: any further ahead than 50 years ago? World J Gastroenterol (2014) 0.82
Clinical epidemiology--how important now? Gut (2005) 0.82
Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? World J Gastroenterol (2006) 0.82
ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol (2017) 0.78
Worldwide Incidence of Colorectal Cancer, Leukemia, and Lymphoma in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis. Gastroenterol Res Pract (2016) 0.75
Overexpression of p53 predicts colorectal neoplasia risk in patients with inflammatory bowel disease and mucosa changes indefinite for dysplasia. Gastroenterol Rep (Oxf) (2015) 0.75
Asymptomatic ileal adenocarcinoma in the setting of undiagnosed Crohn's disease. World J Gastroenterol (2008) 0.75
A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease. J Gastroenterol (2016) 0.75
Hematologic malignancies in the Japanese patients with inflammatory bowel disease. J Gastroenterol (2013) 0.75
Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014. BMJ (2017) 0.75
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology (1994) 3.81
Incidence and prevalence of ulcerative colitis and Crohn's disease in the County of Copenhagen, 1962 to 1978. Gastroenterology (1982) 3.28
Familial occurrence of inflammatory bowel disease. N Engl J Med (1991) 2.95
Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology (1992) 2.86
Long term prognosis in ulcerative colitis--based on results from a regional patient group from the county of Copenhagen. Gut (1985) 2.72
Prognosis in Crohn's disease--based on results from a regional patient group from the county of Copenhagen. Gut (1985) 2.56
Genetic analyses of chromosome 12 loci in Crohn's disease. Gut (2000) 2.30
Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol (1995) 2.21
Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. Scand J Gastroenterol (1992) 2.09
Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut (1994) 2.06
An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol (2001) 1.88
European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut (2006) 1.87
Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls. J Clin Microbiol (2000) 1.85
The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment. A double-blind trial on patients asymptomatic for one year. Scand J Gastroenterol (1973) 1.82
A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa, and cytologic picture of mucosal exudate in ulcerative colitis. Scand J Gastroenterol (1970) 1.79
Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology (1993) 1.74
The prognosis of ulcerative colitis. Scand J Gastroenterol (1974) 1.74
Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol (1991) 1.73
Quality of life in patients receiving home parenteral nutrition. Gut (1999) 1.71
Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut (1994) 1.70
Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol (2000) 1.64
Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease--a population-based study. Aliment Pharmacol Ther (2011) 1.53
Treatment of refractory ulcerative colitis with cyclosporin enemas. Lancet (1989) 1.49
5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology (1982) 1.44
A genetic study of ulcerative colitis. Scand J Gastroenterol (1966) 1.42
Low-dose cyclosporin for Crohn's disease: implications for clinical trials. Aliment Pharmacol Ther (1989) 1.42
Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia (2009) 1.41
MiR-125 in normal and malignant hematopoiesis. Leukemia (2012) 1.41
Histamine content of rectal mucosa in ulcerative colitis. Gut (1967) 1.37
Investigation of inheritance of chronic inflammatory bowel diseases by complex segregation analysis. BMJ (1993) 1.34
Social prognosis in patients with ulcerative colitis. Br Med J (1980) 1.33
Mycobacterium paratuberculosis in intestinal tissue from patients with Crohn's disease demonstrated by a nested primer polymerase chain reaction. Scand J Gastroenterol (1994) 1.32
Clinical appearance at diagnosis of ulcerative colitis and Crohn's disease in a regional patient group. Scand J Gastroenterol (1983) 1.31
East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut (2013) 1.30
Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. Scand J Gastroenterol (1997) 1.28
Ethical aspects of clinical trials: the attitudes of participants in two non-cancer trials. J Intern Med (2000) 1.28
Language, space, and the development of cognitive flexibility in humans: the case of two spatial memory tasks. Cognition (2001) 1.27
Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut (2005) 1.26
Intestinal immunoglobulins in ulcerative colitis. Scand J Gastroenterol (1973) 1.26
Life prospects and quality of life in patients with Crohn's disease. Gut (1987) 1.22
Histological and histochemical changes in the jejunal mucosa in ulcerative colitis. Scand J Gastroenterol (1974) 1.20
Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut (2005) 1.17
Cell density in lamina propria of the colon. A quantitative method applied to normal subjects and ulcerative colitis patients. Scand J Gastroenterol (1970) 1.16
Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther (1994) 1.14
Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol (2003) 1.14
Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol (1996) 1.12
TNFSF15 polymorphisms are associated with susceptibility to inflammatory bowel disease in a new European cohort. Am J Gastroenterol (2009) 1.10
Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology (1990) 1.09
Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther (2011) 1.07
Circulating immune complexes in ulcerative colitis. I. Correlation to disease activity. Clin Exp Immunol (1978) 1.04
Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion (2007) 1.01
Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Am J Gastroenterol (2003) 0.99
Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis. Scand J Gastroenterol (1986) 0.99
The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther (2013) 0.97
Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol Ther (2004) 0.96
Disodium cromoglycate in the treatment of ulcerative colitis and Crohn's disease. Gut (1981) 0.95
Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis. Gut (2006) 0.95
Leucocyte function in ulcerative colitis. Quantitative leucocyte mobilisation to skin windows and in vitro function of blood leucocytes. Gut (1982) 0.93
eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s disease. Aliment Pharmacol Ther (2012) 0.92
Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease. Dig Dis Sci (1994) 0.91
Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices. Aliment Pharmacol Ther (2010) 0.90
Magnetic resonance imaging of Crohn disease: early recognition of treatment response and relapse. Abdom Imaging (1997) 0.88
Bile acid metabolism in patients with Crohn's disease in terminal ileum. Scand J Gastroenterol (1986) 0.88
CEA and carbohydrate antigens in normal and neoplastic colon mucosa. An immunohistochemical study. Acta Pathol Microbiol Immunol Scand A (1987) 0.88
Array-based sequence capture and next-generation sequencing for the identification of primary immunodeficiencies. Scand J Immunol (2012) 0.87
Does the patient appear acutely or chronically ill? An interobserver study of global assessments of hospital patients. Acta Med Scand (1982) 0.87
The leucocyte chemotactic function in patients with ulcerative colitis. Scand J Gastroenterol (1977) 0.87
Familial occurrence of complement dysfunction in Crohn's disease: correlation with intestinal symptoms and hypercatabolism of complement. Gut (1985) 0.86
Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with IBD. Gut (2000) 0.86
Quality of life study in a regional group of patients with Crohn disease. A structured interview study. Scand J Gastroenterol (2000) 0.86
5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol (1987) 0.86
5-Aminosalicylic acid enemas in patients with active ulcerative colitis. Influence of acidity on the kinetic pattern. Scand J Gastroenterol (1984) 0.86
Active Crohn's disease and ulcerative colitis evaluated by low-field magnetic resonance imaging. Scand J Gastroenterol (1998) 0.85
Evaluation of treatment response in active Crohn's disease by low-field magnetic resonance imaging. Abdom Imaging (1999) 0.85
Granulomas of the appendix: is it Crohn's disease? Scand J Gastroenterol (1991) 0.85
Bile acid malabsorption in patients with an ileum reservoir with a long efferent leg to an anal anastomosis. Scand J Gastroenterol (1985) 0.84
Leucocyte scintigraphy to localize inflammatory activity in ulcerative colitis and Crohn's disease. Scand J Gastroenterol (1992) 0.83
Hyperhomocysteinaemia, coagulation pathway activation and thrombophilia in patients with inflammatory bowel disease. Scand J Gastroenterol (2002) 0.83